CPT1A and neoplasm: In studies using orthotopic xenografts from patients with triple-negative breast cancer, blocking carnitine palmitoyltransferase 1 (CPT1), the key enzyme that controls fatty acid oxidation, resulted in reduced tumor growth and prolonged survival periods (50) and a glioblastoma model located in its original anatomical position (51).